

# Join your colleagues for an informative educational program on HAE and FIRAZYR® (icatibant injection)



Please join Dr. Patel in a dynamic discussion about HAE and FIRAZYR in treating acute HAE attacks in adults 18 years of age and older, sponsored by Shire.

This presentation and interactive Q&A session will review:

- **Clinical manifestations and pathophysiology of HAE**
- **Importance of correct diagnosis**
- **Current guidelines for the management of HAE**
- **The role of FIRAZYR in relieving symptoms of an attack**
- **Important Safety Information for FIRAZYR**



## Who:

Pragnesh H. Patel, MD  
Allergy Asthma Specialists, PA  
Altamonte Springs, FL



## When:

Thursday, September 17, 2015  
6:30 PM



## Where:

Ruth's Chris Steak House  
7501 West Sand Lake Road  
Orlando, FL 32819  
(407) 226-3900

**For questions about the program or to register,  
please call toll-free 877-761-7925.**

*To facilitate a meaningful educational discussion, this program is open to healthcare professionals only. Please be advised that spouses and other guests are not permitted to attend. Thank you in advance, and we look forward to your participation.*

This is not a CME program.

## INDICATION

FIRAZYR® (icatibant injection) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

## IMPORTANT SAFETY INFORMATION

### Warnings and precautions

Given the potential for airway obstruction during acute laryngeal HAE attacks, patients should be advised to seek medical attention in an appropriate healthcare facility immediately in addition to treatment with FIRAZYR.

Please see additional Important Safety Information on the reverse, and the accompanying Full Prescribing Information.

Promotional program sponsored by



©2015 Shire. All rights reserved.  
US/FIR-00752a(2) 04/2015

## **IMPORTANT SAFETY INFORMATION,** *continued*

### ***Adverse reactions***

The most commonly reported adverse reactions were injection-site reactions, which occurred in almost all patients (97%) in clinical trials. These injection-site reactions included bruising, hematoma, burning, erythema, hypoesthesia, irritation, numbness, edema, pain, pressure sensation, pruritus, swelling, urticaria, and warmth. Other common adverse reactions included pyrexia (4%), transaminase increase (4%), and dizziness (3%), as well as rash, headache, and nausea.

### ***Drug interactions***

FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. Clinical trials to date have excluded subjects taking ACE inhibitors.

### ***Use in specific populations***

FIRAZYR is classified as pregnancy category C.

There are no adequate and well-controlled studies of FIRAZYR in pregnant women. FIRAZYR should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Because many drugs are excreted in human milk, caution should be exercised when FIRAZYR is administered to a nursing woman.

Clinical studies of FIRAZYR included a limited number of subjects aged 65 and over. Elderly patients are likely to have increased systemic exposure. Reported clinical experience has not identified differences in efficacy and safety between elderly and younger patients.

Safety and effectiveness in patients below 18 years of age have not been established.

### ***Self-administration***

The safety of self-administration was evaluated in a separate, open-label trial in 56 patients with HAE. In this trial, the safety profile of FIRAZYR in patients who self-administered FIRAZYR was similar in nature and frequency to that of patients whose therapy was administered by healthcare professionals.

**Please see accompanying full Prescribing Information .**

**To report suspected adverse events, please contact Shire Human Genetic Therapies, Inc. at 1-866-888-0660 or the FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

**For assistance with medical inquiries about FIRAZYR, please contact Medical Information at 1-866-888-0660 option 2 or [US\\_ShireHGT\\_MedicalInformation@shire.com](mailto:US_ShireHGT_MedicalInformation@shire.com).**

Promotional program sponsored by



©2015 Shire. All rights reserved.  
US/FIR-00752a(2) 04/2015

